Antibiotic adjuvants: multicomponent anti-infective strategies - PubMed (original) (raw)
Review
Antibiotic adjuvants: multicomponent anti-infective strategies
Lindsay Kalan et al. Expert Rev Mol Med. 2011.
Abstract
The unremitting emergence of multidrug-resistant bacterial pathogens highlights a matching need for new therapeutic options. For example, new carbapenemases such as KPC (class A Klebsiella pneumoniae) and NDM-1 (New Delhi metallo-β-lactamase 1) are surfacing, resulting in almost total resistance to β-lactam antibiotics. Furthermore, resistance is quickly disseminated, not only in the healthcare sector, but also within the community at large, because many resistance determinants are carried on mobile genetic elements readily shared among pathogens. The absence of new antibiotics has led to a growing reliance on older, more toxic drugs such as colistin, but resistance to these is already arising. One approach to combat this growing problem is the use of combination drug antibiotic adjuvant therapy, which potentiates the activity of antibiotics. Here, we review the current situation and discuss potential drug combinations that may increase the potency of antibiotics in the future. Adjuvant therapies include antibiotic combinations, synergy between antibiotics and nonantibiotics, inhibition of resistance and molecules that alter the physiology of antibiotic-insensitive cells, such as those in biofilms. We provide a rationale for these multicomponent strategies, highlighting current research and important considerations for their clinical use and pharmacological properties.
Similar articles
- Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae.
Bush K. Bush K. Curr Opin Microbiol. 2010 Oct;13(5):558-64. doi: 10.1016/j.mib.2010.09.006. Epub 2010 Oct 1. Curr Opin Microbiol. 2010. PMID: 20920882 Review. - Antibiotic Adjuvants: Rescuing Antibiotics from Resistance.
Wright GD. Wright GD. Trends Microbiol. 2016 Nov;24(11):862-871. doi: 10.1016/j.tim.2016.06.009. Epub 2016 Jul 15. Trends Microbiol. 2016. PMID: 27430191 Review. - [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
Bedenić B. Bedenić B. Lijec Vjesn. 2005 Jan-Feb;127(1-2):12-21. Lijec Vjesn. 2005. PMID: 16145868 Review. Croatian. - What's new in antibiotic resistance? Focus on beta-lactamases.
Babic M, Hujer AM, Bonomo RA. Babic M, et al. Drug Resist Updat. 2006 Jun;9(3):142-56. doi: 10.1016/j.drup.2006.05.005. Epub 2006 Aug 8. Drug Resist Updat. 2006. PMID: 16899402 Review. - Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
Lode H. Lode H. Int J Clin Pract Suppl. 2002 Mar;(125):10-17; discussion 37-9. Int J Clin Pract Suppl. 2002. PMID: 12014852 Review.
Cited by
- Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics.
Quave CL, Estévez-Carmona M, Compadre CM, Hobby G, Hendrickson H, Beenken KE, Smeltzer MS. Quave CL, et al. PLoS One. 2012;7(1):e28737. doi: 10.1371/journal.pone.0028737. Epub 2012 Jan 5. PLoS One. 2012. PMID: 22242149 Free PMC article. - Antibiotic adjuvants: identification and clinical use.
Bernal P, Molina-Santiago C, Daddaoua A, Llamas MA. Bernal P, et al. Microb Biotechnol. 2013 Sep;6(5):445-9. doi: 10.1111/1751-7915.12044. Epub 2013 Feb 28. Microb Biotechnol. 2013. PMID: 23445397 Free PMC article. Review. No abstract available. - Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.
Shi K, Caldwell SJ, Fong DH, Berghuis AM. Shi K, et al. Front Cell Infect Microbiol. 2013 Jun 25;3:22. doi: 10.3389/fcimb.2013.00022. eCollection 2013. Front Cell Infect Microbiol. 2013. PMID: 23805415 Free PMC article. Review. - Antibacterial and Potentiation Properties of Charge-Optimized Polyrotaxanes for Combating Opportunistic Bacteria.
Qiao J, Liu Z, Purro M, Xiong MP. Qiao J, et al. J Mater Chem B. 2018 Sep 7;6(33):5353-5361. doi: 10.1039/C8TB01610K. Epub 2018 Jul 31. J Mater Chem B. 2018. PMID: 30386619 Free PMC article. - Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon R, Idowu T, Zhanel GG, Schweizer F. Domalaon R, et al. Clin Microbiol Rev. 2018 Mar 14;31(2):e00077-17. doi: 10.1128/CMR.00077-17. Print 2018 Apr. Clin Microbiol Rev. 2018. PMID: 29540434 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical